|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Society AC: Cancer facts & figures
2016. American Cancer Society; Atlanta, GA: 2016
|
|
3
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Blute ML Jr, Damaschke NA and Jarrard DF:
The epigenetics of prostate cancer diagnosis and prognosis: Update
on clinical applications. Curr Opin Urol. 25:83–88. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Draisma G, Etzioni R, Tsodikov A, Mariotto
A, Wever E, Gulati R, Feuer E and de Koning H: Lead time and
overdiagnosis in prostate-specific antigen screening: Importance of
methods and context. J Natl Cancer Inst. 101:374–383. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
PSA-based screening for prostate cancer, .
Too many adverse effects. Prescrire Int. 21:215–217.
2012.PubMed/NCBI
|
|
7
|
Garg AD, Martin S, Golab J and Agostinis
P: Danger signalling during cancer cell death: Origins, plasticity
and regulation. Cell Death Differ. 21:26–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sehrawat A, Roy R, Pore SK, Hahm ER,
Samanta SK, Singh KB, Kim SH, Singh K and Singh SV: Mitochondrial
dysfunction in cancer chemoprevention by phytochemicals from
dietary and medicinal plants. Semin Cancer Biol. 47:147–153. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guerra F, Guaragnella N, Arbini AA, Bucci
C, Giannattasio S and Moro L: Mitochondrial dysfunction: A novel
potential driver of epithelial-to-mesenchymal transition in cancer.
Front Oncol. 7:2952017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ježek J, Cooper KF and Strich R: Reactive
oxygen species and mitochondrial dynamics: The yin and yang of
mitochondrial dysfunction and cancer progression. Antioxidants
(Basel). 7(pii): E132018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang X, Zhong W, Huang H, He H, Jiang F,
Chen Y, Yue F, Zou J, Li X, He Y, et al: Autophagy defects
suggested by low levels of autophagy activator MAP1S and high
levels of autophagy inhibitor LRPPRC predict poor prognosis of
prostate cancer patients. Mol Carcinog. 54:1194–1204. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang X, Li X, Huang H, Jiang F, Lin Z, He
H, Chen Y, Yue F, Zou J, He Y, et al: Elevated levels of
mitochondrion-associated autophagy inhibitor LRPPRC are associated
with poor prognosis in patients with prostate cancer. Cancer.
120:1228–1236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Beckman KB, Caberto C, Kazma R,
Lum-Jones A, Haiman CA, Le Marchand L, Stram DO, Saxena R and Cheng
I: Association of genes, pathways, and haplogroups of the
mitochondrial genome with the risk of colorectal cancer: The
multiethnic cohort. PLoS One. 10:e01367962015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Burch TC, Rhim JS and Nyalwidhe JO: Novel
altered mitochondrial genes in prostate cancer progression. Cancer
Res. 75:2015. View Article : Google Scholar
|
|
15
|
Genecards: Summaries for PTCD3 Gene.
https://www.genecards.org/cgi-bin/carddisp.pl?gene=PTCD3August
8–2018
|
|
16
|
Lightowlers RN and Chrzanowska-Lightowlers
ZM: Human pentatricopeptide proteins: Only a few and what do they
do? RNA Biol. 10:1433–1438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rackham O, Davies SM, Shearwood AM,
Hamilton KL, Whelan J and Filipovska A: Pentatricopeptide repeat
domain protein 1 lowers the levels of mitochondrial leucine tRNAs
in cells. Nucleic Acids Res. 37:5859–5867. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Madhavan S, Gusev Y, Singh S and Riggins
RB: ERRγ target genes are poor prognostic factors in
Tamoxifen-treated breast cancer. J Exp Clin Cancer Res. 34:452015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
D'Andrea A, Gritti I, Nicoli P, Giorgio M,
Doni M, Conti A, Bianchi V, Casoli L, Sabò A, Mironov A, et al: The
mitochondrial translation machinery as a therapeutic target in
Myc-driven lymphomas. Oncotarget. 7:72415–72430. 2016.PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Esfahani M, Ataei N and Panjehpour M:
Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J
Cancer Prev. 16:2601–2611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baade PD, Youlden DR and Krnjacki LJ:
International epidemiology of prostate cancer: Geographical
distribution and secular trends. Mol Nutr Food Res. 53:171–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Manna S: An overview of pentatricopeptide
repeat proteins and their applications. Biochimie. 113:93–99. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baggio F, Bratic A, Mourier A, Kauppila
TE, Tain LS, Kukat C, Habermann B, Partridge L and Larsson NG:
Drosophila melanogaster LRPPRC2 is involved in coordination of
mitochondrial translation. Nucleic Acids Res. 42:13920–13938. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zong WX, Rabinowitz JD and White E:
Mitochondria and cancer. Mol Cell. 61:667–676. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oran AR, Adams CM, Zhang XY, Gennaro VJ,
Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa
MR, et al: Multi-focal control of mitochondrial gene expression by
oncogenic MYC provides potential therapeutic targets in cancer.
Oncotarget. 7:72395–72414. 2016. View Article : Google Scholar : PubMed/NCBI
|
